Shares of Neumora Therapeutics Inc. (NMRA), a clinical-stage biopharmaceutical company focused on brain diseases, are down over 50% from their 52-week high of $21, recorded in March of this year, and trade around $9. With several key clinical trial events on the horizon, it could be worth keeping an eye on this stock.
The company's lead drug candidate, Navacaprant (NMRA-140), a kappa opioid receptor (KOR) antagonist, is currently being evaluated in a pivotal Phase 3 program for Major Depressive Disorder, dubbed KOASTAL.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com